Coronaviruses: A patent dataset report for research and development (R&amp;D) analysis

Martínez, Fanny López; Camargo-Amado, Rubén J.; Gutiérrez, Óscar Eligio Villanueva

doi:10.1016/j.dib.2020.105551

Cited by 12 publications

(12 citation statements)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Herein, we expand on recent early attempts to link propositions to overcome the crisis and intellectual property (e.g., Machuca‐Martinez et al, 2020; Tietze et al, 2020). The findings from the patent analytics presented above confirm Cefis and Marsili (2019) in that technological innovations might trigger firms’ survivals in crises: ‘R&D investment is shown to be a poor choice for general firms to survive; however, it is an effective strategy for firms that are innovative and capable of producing intellectual properties during recessionary periods’ (Jung et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…This ensures interpreting patents as strategic assets, which allow leveraging existing capabilities and deploying promising business opportunities (Rivette and Kline, 2000; Di Minin and Faems, 2013; Bican et al 2017). However, this strategic view of intellectual property is underrepresented in the extent literature on innovation management in crises: Only a few early attempts to link propositions to overcome the crisis and intellectual property exist (e.g., Machuca‐Martinez et al, 2020; Tietze et al, 2020). Although scholars have acknowledged that patent information can be used, among others, for technological forecasting, business planning, or strategic R&D planning, the value and use of patent information in crises have largely been overlooked, resulting in a knowledge gap (Campbell, 1983; Ashton and Sen, 1988; Ernst, 2003).…”

Section: Theoretical Backgroundmentioning

confidence: 99%

See 1 more Smart Citation

Innovation management in crisis: patent analytics as a response to the COVID‐19 pandemic

et al. 2020

View full text Add to dashboard Cite

Crises like the COVID‐19 pandemic affect firms’ innovation management and decision making. On the downside, crises lead to detriments like budget constraints, to which firms often respond by reducing their innovation activities. On the upside, crises are opportunities, where some firms exploiting changing market requirements and necessities excel. No matter in which direction, decision makers must react quickly but often rely on ad‐hoc decisions or even gut feeling when drafting their crisis response strategies. Through a series of distinct cases, we demonstrate that innovation management may fill this void through patent analytics. Drawing on biochemical expertise, we particularly describe the functions and effects of COVID‐19. To counter downside detriments, firms may circumvent budget constraints by discerning patents that can be (1) monetized, for example via sales or licensing deals, or (2) abandoned to achieve cost‐savings, allowing firms to maintain their innovation activities. To realize upside opportunities, firms and governments may use patent analytics to detect key biotechnology firms that are likely to successfully develop treatments and vaccinations against pandemics like COVID‐19. Promulgated U.S. interest in relocating foreign firms to the United States is not without technological and commercial reasoning. Herein, the insights of this study contribute to a better understanding of the use of patent information, such as smart patent indicators, harmonized patent data, novel annuity fee measures, and hand‐collected datasets of COVID‐19 and related antibodies’ patents to the management of innovation in times of crisis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Theoretical Backgroundmentioning

confidence: 99%

Innovation management in crisis: patent analytics as a response to the COVID‐19 pandemic

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At the same time, drug research and design (R&D) and clinical trials are in full swing. The intense development of new therapies is marked by the active use of intellectual property rights along with robust R&D investments [1].…”

Section: Introductionmentioning

confidence: 99%

“…Further, coronaviruses have commonalities, which are all causing respiratory diseases. In view of the commonness, non-COVID-19 patent documents may be a useful source of information for the R&D of approaches to combating COVID-19 [5].…”

Section: Introductionmentioning

confidence: 99%

“…Previous patent studies have only focused on several subclasses of coronavirus [6][7][8][9], such as Choi et al focused on the MERS-CoV vaccine patents that may have higher potential for commercialization [10]. And no comprehensive patent analyses have been conducted in this area before [5,11]. To fill the gap, we provide an overview of the current trends under development, focusing on the patent landscape of human coronavirus in the temporal, spatial, and technological dimensions, as well as employing a knowledge flow network perspective [12] by using information citations between patents, which may provide a reference for relevant decision making by researchers, investors, and policymakers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Global landscape of patents related to human coronaviruses

Liu¹,

Gu²,

Islam³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

At present, the COVID-19 pandemic is running rampant, having caused 2.18 million deaths. Characterizing the global patent landscape of coronaviruses is essential not only for informing research and policy, given the current pandemic crisis, but also for anticipating important future developments. While patents are a promising indicator of technological knowledge production widely used in innovation research, they are often an underused resource in biological sciences. In this study, we present a patent landscape for the seven coronaviruses known to infect humans. The information included in this paper provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines along with a deeper discussion of intellectual property rights under epidemic conditions. The results show that there has been a rapid increase in human coronavirus patents, especially COVID-19 patents. China and the United States play an outstanding role in global cooperation and patent application. The leading role of academic institutions and government is increasingly apparent. Notable technological issues related to human coronaviruses include pharmacochemical treatment, diagnosis of viral infection, viral-vector vaccines, and traditional Chinese medicine. Furthermore, a critical challenge lies in balancing commercial competition, enterprise profit, knowledge sharing, and public interest.

show abstract

Investment decisions and passive portfolio construction utilizing patent analytics: A multi-case study on COVID-19 treatment technologies

Guderian,

Posth,

Grob

2023

The Quarterly Review of Economics and Finance

View full text Add to dashboard Cite

Coronaviruses: A patent dataset report for research and development (R&D) analysis

Cited by 12 publications

References 10 publications

Innovation management in crisis: patent analytics as a response to the COVID‐19 pandemic

Innovation management in crisis: patent analytics as a response to the COVID‐19 pandemic

Global landscape of patents related to human coronaviruses

Investment decisions and passive portfolio construction utilizing patent analytics: A multi-case study on COVID-19 treatment technologies

Contact Info

Product

Resources

About